Jia G - Search Results

1

EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma.

Yuan L, Li S, Chen Q, Xia T, Luo D, Li L, Liu S, Guo S, Liu L, Du C, Jia G, Li X, Lu Z, Yang Z, Liu H, Mai H, Tang L. Yuan L, et al. Among authors: jia g. Cell Death Differ. 2022 Aug;29(8):1513-1527. doi: 10.1038/s41418-022-00939-8. Epub 2022 Feb 1. Cell Death Differ. 2022. PMID: 35105963 Free PMC article.

2

Intensive Local Radiotherapy Is Associated With Better Local Control and Prolonged Survival in Bone-Metastatic Nasopharyngeal Carcinoma Patients.

Li XY, Jia GD, Sun XS, Guo SS, Liu LT, Liu SL, Yan JJ, Luo DH, Sun R, Guo L, Mo HY, Tang LQ, Chen QY, Mai HQ. Li XY, et al. Front Oncol. 2020 Mar 20;10:378. doi: 10.3389/fonc.2020.00378. eCollection 2020. Front Oncol. 2020. PMID: 32266152 Free PMC article.

3

Establishment of a prognostic nomogram to identify optimal candidates for local treatment among patients with local recurrent nasopharyngeal carcinoma.

Sun XS, Liang YJ, Jia GD, Liu SL, Liu LT, Guo SS, Sun R, Luo DH, Chen QY, Tang LQ, Mai HQ. Sun XS, et al. Oral Oncol. 2020 Jul;106:104711. doi: 10.1016/j.oraloncology.2020.104711. Epub 2020 Apr 13. Oral Oncol. 2020. PMID: 32298996

4

Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [¹⁸ F]-fluorodeoxyglucose positron emission tomography.

Xie HJ, Yu YF, Sun XS, Jia GD, Luo DH, Sun R, Liu LT, Guo SS, Liu SL, Chen QY, Tang LQ, Mai HQ. Xie HJ, et al. Cancer Med. 2020 Dec;9(23):8852-8863. doi: 10.1002/cam4.3500. Epub 2020 Oct 9. Cancer Med. 2020. PMID: 33034945 Free PMC article.

5

Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy.

Yang JH, Sun XS, Xiao BB, Liu LT, Guo SS, Liang JD, Jia GD, Tang LQ, Chen QY, Mai HQ. Yang JH, et al. BMC Cancer. 2021 May 11;21(1):534. doi: 10.1186/s12885-021-08246-0. BMC Cancer. 2021. PMID: 33975558 Free PMC article.

6

Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA.

Liu LT, Liang YJ, Guo SS, Xie Y, Jia GD, Wen DX, Tang LQ, Chen QY, Mai HQ. Liu LT, et al. Head Neck. 2022 Jan;44(1):34-45. doi: 10.1002/hed.26897. Epub 2021 Oct 12. Head Neck. 2022. PMID: 34636116

7

Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.

Li XY, Luo DH, Guo L, Mo HY, Sun R, Guo SS, Liu LT, Yang ZC, Yang JH, Qiu F, Sun XS, Wang P, Liu Q, Li JB, Tang QN, Lin C, Yang Q, Liu SL, Liang YJ, Jia GD, Wen DX, Guo CY, Yan JJ, Zhao C, Chen QY, Tang LQ, Mai HQ. Li XY, et al. J Clin Oncol. 2022 Apr 10;40(11):1163-1173. doi: 10.1200/JCO.21.01467. Epub 2022 Jan 6. J Clin Oncol. 2022. PMID: 34990291 Clinical Trial.

8

Clinical characteristics and prognostic factors affecting survival after radical radiotherapy for early and late post-treatment metastatic nasopharyngeal carcinoma.

Jia GD, Sun XS, Li XY, Liu SL, Yang JH, Chen QY, Yuan L, Mai HQ. Jia GD, et al. BMC Cancer. 2023 Jan 3;23(1):7. doi: 10.1186/s12885-022-10494-7. BMC Cancer. 2023. PMID: 36597072 Free PMC article.

9

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.

Liu LT, Liu H, Huang Y, Yang JH, Xie SY, Li YY, Guo SS, Qi B, Li XY, Chen DP, Jin F, Sun XS, Yang ZC, Liu SL, Luo DH, Li JB, Liu Q, Wang P, Guo L, Mo HY, Qiu F, Yang Q, Liang YJ, Jia GD, Wen DX, Yan JJ, Zhao C, Chen QY, Sun R, Tang LQ, Mai HQ. Liu LT, et al. Lancet Oncol. 2023 Jul;24(7):798-810. doi: 10.1016/S1470-2045(23)00232-2. Epub 2023 Jun 5. Lancet Oncol. 2023. PMID: 37290468 Clinical Trial.

10

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.

Yuan L, Jia GD, Lv XF, Xie SY, Guo SS, Lin DF, Liu LT, Luo DH, Li YF, Deng SW, Guo L, Zeng MS, Cai XY, Liu SL, Sun XS, Li XY, Li SC, Chen QY, Tang LQ, Mai HQ. Yuan L, et al. Nat Commun. 2023 Aug 14;14(1):4893. doi: 10.1038/s41467-023-40402-x. Nat Commun. 2023. PMID: 37580352 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,103 results

Search Page